1
|
Zeller MP, Barty R, Dunbar NM, Elahie A, Flanagan P, Garritsen H, Kutner JM, Pagano MB, Pogłód R, Rogers TS, Staves J, van Wordragen-Vlaswinkel M, Zwaginga JJ, Murphy MF, Heddle NM, Yazer MH. An international investigation into AB plasma administration in hospitals: how many AB plasma units were infused? The HABSWIN study. Transfusion 2017; 58:151-157. [DOI: 10.1111/trf.14368] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/16/2017] [Revised: 08/24/2017] [Accepted: 08/24/2017] [Indexed: 11/28/2022]
Affiliation(s)
- Michelle P. Zeller
- McMaster Centre for Transfusion Research; McMaster University; Hamilton Ontario Canada
- Canadian Blood Services; Ancaster Ontario Canada
| | - Rebecca Barty
- McMaster Centre for Transfusion Research; McMaster University; Hamilton Ontario Canada
| | | | | | | | - Henk Garritsen
- Institute for Clinical Transfusion Medicine, Municipal Hospital Braunschweig; Braunschweig Germany
- Fraunhofer Institute for Surfaces Engineering and Thin Films IST; Braunschweig Germany
| | | | | | - Ryszard Pogłód
- Institute of Hematology and Transfusion Medicine; Warsaw Poland
| | | | - Julie Staves
- Oxford University Hospitals NHS Foundation Trust; Oxford UK
| | - Maria van Wordragen-Vlaswinkel
- Department of Immunohematology and Blood Transfusion; Leiden University Medical Center and the Center for Clinical Transfusion Research, Sanquin Research-LUMC; Leiden the Netherlands
| | - Jaap Jan Zwaginga
- Department of Immunohematology and Blood Transfusion; Leiden University Medical Center and the Center for Clinical Transfusion Research, Sanquin Research-LUMC; Leiden the Netherlands
| | | | - Nancy M. Heddle
- McMaster Centre for Transfusion Research; McMaster University; Hamilton Ontario Canada
| | - Mark H. Yazer
- University of Pittsburgh and the Institute for Transfusion Medicine; Pittsburgh Pennsylvania
| | | |
Collapse
|
2
|
Cohn C, Dumont L, Lozano M, Marks D, Johnson L, Ismay S, Bondar N, T'Sas F, Yokoyama A, Kutner J, Acker J, Bohonek M, Sailliol A, Martinaud C, Pogłód R, Antoniewicz-Papis J, Lachert E, Pun P, Lu J, Cid J, Guijarro F, Puig L, Gerber B, Alberio L, Schanz U, Buser A, Noorman F, Zoodsma M, van der Meer P, de Korte D, Wagner S, O'Neill M. Vox Sanguinis International Forum on platelet cryopreservation. Vox Sang 2017; 112:e69-e85. [DOI: 10.1111/vox.12532] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/22/2023]
Affiliation(s)
| | | | | | - D.C. Marks
- Australian Red Cross Blood Service; 17 O'Riordan Street Alexandria NSW 2015 Australia
| | - L. Johnson
- Australian Red Cross Blood Service; 17 O'Riordan Street Alexandria NSW 2015 Australia
| | - S. Ismay
- Australian Red Cross Blood Service; 17 O'Riordan Street Alexandria NSW 2015 Australia
| | - N. Bondar
- Australian Red Cross Blood Service; 17 O'Riordan Street Alexandria NSW 2015 Australia
| | - F. T'Sas
- HMRA - Service Militaire de Transfusion Sanguine; Rue Bruyn 1 1120 Bruxelles Belgique
| | - A.P.H. Yokoyama
- Departamento de Hemoterapia; Hospital Israelita Albert Einstein; Av. Albert Einstein, 627 Sao Paulo SP 05651-901 Brazil
| | - J.M. Kutner
- Departamento de Hemoterapia; Hospital Israelita Albert Einstein; Av. Albert Einstein, 627 Sao Paulo SP 05651-901 Brazil
| | - J.P. Acker
- Canadian Blood Services; 8249-114 Street Edmonton AB T6G 2R8 Canada
| | - M. Bohonek
- Department of Hematology and Blood Transfusion; Military University Hospital Prague; U Vojenske nemocnice 1200 Prague 169 02 Czech Republic
| | - A. Sailliol
- French Military Blood Institute; 1 rue de Lieutenant Batany Clamart 92140 France
| | - C. Martinaud
- French Military Blood Institute; 1 rue de Lieutenant Batany Clamart 92140 France
| | - R. Pogłód
- Zakład Transfuzjologii; Instytut Hematologii i Transfuzjologii; ul. I. Gandhi 14 Warszawa 02-776 Poland
| | - J. Antoniewicz-Papis
- Institute of Hematology and Transfusion Medicine; Indiry Gandhi 14 Warsaw 02-776 Poland
| | - E. Lachert
- Institute of Hematology and Transfusion Medicine; Indiry Gandhi 14 Warsaw 02-776 Poland
| | - P.B.L. Pun
- Defence Medical & Environmental Research Institute; DSO National Laboratories (Kent Ridge); 27 Medical Drive Singapore 117510
| | - J. Lu
- Defence Medical & Environmental Research Institute; DSO National Laboratories (Kent Ridge); 27 Medical Drive Singapore 117510
| | - J. Cid
- Apheresis Unit; Department of Hemotherapy and Hemostasis; ICMHO; Hospital Clínic; Villarroel 170 Barcelona Catalonia 08036 Spain
| | - F. Guijarro
- Apheresis Unit; Department of Hemotherapy and Hemostasis; ICMHO; IDIBAPS; Hospital Clínic; University of Barcelona; Barcelona Spain
| | - L. Puig
- Banc de Sang i Teixits de Catalunya; Transfusion Safety Laboratory; Barcelona Spain
| | - B. Gerber
- Division of Hematology; Oncology Institute of Southern Switzerland; Bellinzona CH-6500 Switzerland
| | - L. Alberio
- Division of Hematology and Central Hematology Laboratory; CHUV; Lausanne University Hospital; Lausanne Switzerland
| | - U. Schanz
- Division of Hematology; University and University Hospital Zurich; Zurich Switzerland
| | - A. Buser
- Hematology; University Hospital Basel; Basel Switzerland
| | - F. Noorman
- Military Blood Bank; Plesmanlaan 1c 2333 BZ The Netherlands
| | - M. Zoodsma
- Military Blood Bank; Plesmanlaan 1c 2333 BZ The Netherlands
| | - P.F. van der Meer
- Department of Product and Process Development; Sanquin Blood Bank; Plesmanlaan 125 Amsterdam 1066 CX The Netherlands
| | - D. de Korte
- Sanquin Blood Bank North West Region; Plesmanlaan 125 Amsterdam 1066 CX The Netherlands
| | - S. Wagner
- Transfusion Innovation Dept.; American Red Cross Holland Lab; 15601 Crabbs Branch Way Rockville MD 20855 USA
| | - M. O'Neill
- American Red Cross Medical Office; 180 Rustcraft Rd Dedham MA 020206 USA
| |
Collapse
|
3
|
Cohn CS, Dumont LJ, Lozano M, Marks DC, Johnson L, Ismay S, Bondar N, T'Sas F, Yokoyama APH, Kutner JM, Acker JP, Bohonek M, Sailliol A, Martinaud C, Pogłód R, Antoniewicz-Papis J, Lachert E, Pun PBL, Lu J, Cid J, Guijarro F, Puig L, Gerber B, Alberio L, Schanz U, Buser A, Noorman F, Zoodsma M, van der Meer PF, de Korte D, Wagner S, O'Neill M. Vox Sanguinis International Forum on platelet cryopreservation: Summary. Vox Sang 2017; 112:684-688. [PMID: 28929502 DOI: 10.1111/vox.12533] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
- C S Cohn
- Department of Laboratory Medicine and Pathology, University of Minnesota, D242 Mayo Building, MMC 609, 420 Delaware Street SE, Minneapolis, MN, 55455, USA
| | - L J Dumont
- Blood Systems Research Institute Denver, 717 Yosemite Street, Denver, CO, 80230, USA
| | - M Lozano
- Department of Hemotherapy and Hemostasis, University Clinic Hospital, University of Barcelona, 08036, Barcelona, Spain
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
4
|
Zeller MP, Barty R, Aandahl A, Apelseth TO, Callum J, Dunbar NM, Elahie A, Garritsen H, Hancock H, Kutner JM, Manukian B, Mizuta S, Okuda M, Pagano MB, Pogłód R, Rushford K, Selleng K, Sørensen CH, Sprogøe U, Staves J, Weiland T, Wendel S, Wood EM, van de Watering L, van Wordragen‐Vlaswinkel M, Ziman A, Jan Zwaginga J, Murphy MF, Heddle NM, Yazer MH. An international investigation into O red blood cell unit administration in hospitals: the GRoup O Utilization Patterns (GROUP) study. Transfusion 2017; 57:2329-2337. [DOI: 10.1111/trf.14255] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/24/2017] [Revised: 05/11/2017] [Accepted: 05/14/2017] [Indexed: 10/19/2022]
Affiliation(s)
- Michelle P. Zeller
- McMaster Centre for Transfusion ResearchMcMaster UniversityHamilton Ontario Canada
- Canadian Blood ServicesAncaster Ontario Canada
| | - Rebecca Barty
- McMaster Centre for Transfusion ResearchMcMaster UniversityHamilton Ontario Canada
| | | | | | - Jeannie Callum
- Sunnybrook Health Sciences Centre, Department of Laboratory Medicine and Pathobiology, University of TorontoToronto Ontario Canada
| | | | | | - Henk Garritsen
- Institute for Clinical Transfusion MedicineMunicipal Hospital Braunschweig
- Helmholtz Centre for Infection ResearchBraunschweig Germany
| | - Helen Hancock
- UC Health, University of Cincinnati Medical CenterCincinnati Ohio
| | | | - Belinda Manukian
- UF Health Shands HospitalUniversity of FloridaGainsville Florida
| | | | | | | | - Ryszard Pogłód
- Institute of Hematology and Transfusion MedicineWarsaw Poland
| | | | | | | | - Ulrik Sprogøe
- South Danish Transfusion Service & Tissue CenterOdense University HospitalOdense Denmark
| | - Julie Staves
- Oxford University Hospitals NHS Foundation TrustOxford United Kingdom
| | | | | | | | | | - Maria van Wordragen‐Vlaswinkel
- Leiden University Medical Center and Center for Clinical Transfusion ResearchSanquin Research, and the Department of Immunohematology and Blood Transfusion, Leiden University Medical CenterLeiden The Netherlands
| | - Alyssa Ziman
- Wing‐Kwai and Alice Lee‐Tsing Chung Transfusion Service, Department of Pathology and Laboratory Medicine, David Geffen School of Medicine, University of California at Los AngelesLos Angeles, California
| | - Jaap Jan Zwaginga
- Leiden University Medical Center and Center for Clinical Transfusion ResearchSanquin Research, and the Department of Immunohematology and Blood Transfusion, Leiden University Medical CenterLeiden The Netherlands
| | - Michael F. Murphy
- Oxford University Hospitals NHS Foundation TrustOxford United Kingdom
| | - Nancy M. Heddle
- McMaster Centre for Transfusion ResearchMcMaster UniversityHamilton Ontario Canada
| | - Mark H. Yazer
- University of Pittsburgh and the Institute for Transfusion MedicinePittsburgh Pennsylvania
| | | |
Collapse
|
5
|
Yazer MH, Lozano M, Fung M, Kutner J, Murphy MF, Oveland Apelseth T, Pogłód R, Selleng K, Tinmouth A, Wendel S, Yahalom V. An international survey on the role of the hospital transfusion committee. Transfusion 2017; 57:1280-1287. [PMID: 28236313 DOI: 10.1111/trf.14033] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/17/2016] [Revised: 12/21/2016] [Accepted: 12/21/2016] [Indexed: 12/01/2022]
Abstract
BACKGROUND Hospital transfusion committees (HTCs) can oversee all aspects of transfusion practice at a hospital. This survey sought to identify which quality variables were being reported at HTCs around the world. STUDY DESIGN AND METHODS A working party composed of members of the Biomedical Excellence for Safer Transfusion (BEST) collaborative developed a survey of quality variables that could be potentially presented at HTC meetings. The survey was electronically sent to all BEST members who were encouraged to complete it if they were active on an HTC and to send it to other colleagues with similar experience. An expert panel was convened to determine which quality variables are the most important for review at HTC meetings. RESULTS There were 121 respondents; the majority were from Europe (52%), Asia (19%), or North America (19%). Most respondents (68%) were at university hospitals. Of the 117 (97%) respondents with an HTC, the committee most often met quarterly (42%) and reviewed transfusion reactions (79%) and risk management-reported events (52%). The HTCs most commonly included transfusion medicine physicians, anesthesiologists, and other physicians who regularly transfuse blood products. Some of the most commonly reported quality variables included number of blood products transfused, wasted, and expired and the number of improperly labeled specimens. The expert panel analysis revealed that some variables that were deemed important were not being frequently reported at HTCs. CONCLUSION There is variability in the variables being reported at HTCs around the world with some important variables not frequently reported.
Collapse
Affiliation(s)
- Mark H Yazer
- Department of Pathology, University of Pittsburgh and the Institute for Transfusion Medicine, Pittsburgh, Pennsylvania
| | - Miguel Lozano
- Department of Hemotherapy and Hemostasis, University Clinic Hospital, IDIBAPS, University of Barcelona, Barcelona, Spain
| | - Mark Fung
- University of Vermont Medical Center, Burlington, Vermont
| | - Jose Kutner
- Department of Hemotherapy and Cell Therapy, Hospital Israelita Albert Einstein, Sao Paulo, Brazil
| | - Michael F Murphy
- NHS Blood & Transplant, Oxford University Hospitals NHS Foundation Trust, and University of Oxford, Oxford, UK
| | - Torunn Oveland Apelseth
- Laboratory of Clinical Biochemistry and Department of Immunology and Transfusion Medicine, Haukeland University Hospital, Bergen, Norway
| | - Ryszard Pogłód
- Department of Transfusion Medicine, Institute of Hematology and Transfusion Medicine, Warsaw, Poland
| | - Kathleen Selleng
- Department of Transfusion Medicine, Institute of Immunology and Transfusion Medicine, University Medicine Greifswald, Greifswald, Germany
| | - Alan Tinmouth
- Department of Medicine and Department of Laboratory Medicine & Pathology, University of Ottawa, Ottawa, Ontario, Canada
| | | | - Vered Yahalom
- Department of Transfusion Medicine and Apheresis, Rabin Medical Center, Petach Tikva, Israel
| | | |
Collapse
|
6
|
Pogłód R, Rosiek A, Łętowska M. [Emerging infectious diseases in the context of blood safety]. ACTA ACUST UNITED AC 2013; 44:284-293. [PMID: 32226059 PMCID: PMC7094095 DOI: 10.1016/j.achaem.2013.07.022] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/31/2013] [Accepted: 07/02/2013] [Indexed: 11/24/2022]
Affiliation(s)
- Ryszard Pogłód
- Instytut Hematologii i Transfuzjologii, Dyrektor: prof. dr hab n.med. Krzysztof Warzocha, Warszawa, Polska
| | - Aleksandra Rosiek
- Instytut Hematologii i Transfuzjologii, Dyrektor: prof. dr hab n.med. Krzysztof Warzocha, Warszawa, Polska
| | - Magdalena Łętowska
- Instytut Hematologii i Transfuzjologii, Dyrektor: prof. dr hab n.med. Krzysztof Warzocha, Warszawa, Polska
| |
Collapse
|
7
|
Pogłód R, Lętowska M. Plasma in Poland: Production, use and safety. Transfus Apher Sci 2011; 45:227-8. [PMID: 22071226 DOI: 10.1016/j.transci.2011.10.021] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
- Ryszard Pogłód
- Department of Transfusion Medicine, Institute of Hematology and Transfusion Medicine, 14 I. Gandhi Str., 02-776 Warsaw, Poland.
| | | |
Collapse
|
8
|
Kraj M, Kopeć-Szlęzak J, Pogłód R, Kruk B. Flow cytometric immunophenotypic characteristics of plasma cell leukemia. Folia Histochem Cytobiol 2011; 49:168-82. [DOI: 10.5603/fhc.2011.0024] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
|
9
|
Kraj M, Kopeć-Szlęzak J, Pogłód R, Kruk B. Flow cytometric immunophenotypic characteristics of 36 cases of plasma cell leukemia. Leuk Res 2011; 35:169-76. [PMID: 20553988 DOI: 10.1016/j.leukres.2010.04.021] [Citation(s) in RCA: 32] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/14/2010] [Revised: 04/22/2010] [Accepted: 04/23/2010] [Indexed: 12/13/2022]
Abstract
Prospective flow cytometric analysis of antigens expression on bone marrow and peripheral blood plasma cells of 36 plasma cell leukemia (PCL) patients enabled to establish the following immunophenotype of leukemic plasma cell: CD38(++), CD138(+), CD54(+), CD49d(+), CD29(+), CD44(+), CD126(+), CD19(-), CD45(-). In one-third of patients PCL cells express CD56, CD71 and CD117. Expression of CD54 on plasma cells was higher as compared to expression of adhesion molecules CD11a, CD18 and CD11b (p<0.01). Expression of CD18, CD11a, CD11b was lower on bone marrow and higher on peripheral blood cells. In conclusion, impaired expression of adhesion molecules such as CD11a/CD18 or CD56 may explain hematogenic dissemination characterizing PCL.
Collapse
Affiliation(s)
- Maria Kraj
- Department of Hematology, Institute of Hematology and Transfusion Medicine, 14 I Gandhi Street, 02-776 Warsaw, Poland.
| | | | | | | |
Collapse
|
10
|
Siński E, Welc-Faleciak R, Pogłód R. Babesia spp. infections transmitted through blood transfusion. Wiad Parazytol 2011; 57:77-81. [PMID: 21682090] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/30/2023]
Abstract
Babesiosis in humans is caused by infection with various species of Babesia (Apicomplexa, Piroplasmida), mainly transmitted by an arthropod vector--Ixodes spp. ticks. This review will focus on blood transfusion as another mode of Babesia transmission, especially in endemic areas, as well as the impact of human babesiosis on transfusion medicine.
Collapse
Affiliation(s)
- Edward Siński
- Department of Parasitology, Faculty of Biology, University of Warsaw, 1 Miecznikowa Street, 02-096 Warsaw.
| | | | | |
Collapse
|
11
|
Pogłód R, Kraj M, Kruk B, Hagedorna-Tronina R, Łetowska M, Warzocha K. Complete remission following treatment with bortezomib, doxorubicin, dexamethasone and autologous stem cell transplant in patient with immunoglobulin E multiple myeloma. Leuk Lymphoma 2010; 51:2291-4. [PMID: 20929320 DOI: 10.3109/10428194.2010.523128] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
|
12
|
Kraj M, Sokołowska U, Kopeć-Szlęzak J, Pogłód R, Kruk B, Woźniak J, Szpila T. Clinicopathological correlates of plasma cell CD56 (NCAM) expression in multiple myeloma. Leuk Lymphoma 2009; 49:298-305. [DOI: 10.1080/10428190701760532] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
13
|
Warzocha K, Kraj M, Pogłód R, Szpila T, Mendek-Czajkowska E, Chełstowska M, Tronina RH. Efficacy and safety of thalidomide in the treatment of multiple myeloma. Acta Pol Pharm 2008; 65:771-774. [PMID: 19172865] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/27/2023]
Affiliation(s)
- Krzysztof Warzocha
- Institute of Hematology and Transfusion Medicine, 14 Indira Gandhi St., 02-776 Warsaw, Poland
| | | | | | | | | | | | | |
Collapse
|
14
|
Warzocha K, Kraj M, Pogłód R, Kwaśniak B. Bortezomib in multiple myeloma: treatment and retreatment. A single center experience. Acta Pol Pharm 2008; 65:753-756. [PMID: 19172860] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/27/2023]
Affiliation(s)
- Krzysztof Warzocha
- Institute of Hematology and Transfusion Medicine, 14 Indira Gandhi St., 02-776 Warsaw, Poland
| | | | | | | |
Collapse
|
15
|
Kraj M, Pogłód R, Maj S, Owczarska K. The incidence of jaw osteonecrosis in multiple myeloma patients treated with bisphosphonates. Acta Pol Pharm 2006; 63:450-2. [PMID: 17357613] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/14/2023]
Affiliation(s)
- Maria Kraj
- Department of Haematology Institute of Haematology and Blood Transfusion, ul. Chocimska 5, Warszawa, Poland.
| | | | | | | |
Collapse
|
16
|
Warzocha K, Kraj M, Pogłód R, Sokołowska U. The efficacy and safety of bortezomib (velcade) in the treatment of relapsed multiple mye. Acta Pol Pharm 2006; 63:452-5. [PMID: 17357614] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/14/2023]
Affiliation(s)
- Krzysztof Warzocha
- Institute of Haematology and Blood Transfusion, 5 Chocimska Str., 00-957 Warsaw, Poland
| | | | | | | |
Collapse
|
17
|
Kraj M, Owczarska K, Sokołowska U, Centkowski P, Pogłód R, Kruk B. Correlation of osteoprotegerin and sRANKL concentrations in serum and bone marrow of multiple myeloma patients. Arch Immunol Ther Exp (Warsz) 2005; 53:454-64. [PMID: 16314829] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/10/2005] [Accepted: 05/10/2005] [Indexed: 05/05/2023]
Abstract
INTRODUCTION Recent studies suggest that multiple myeloma (MM) triggers osteoclastogenesis by disrupting the balance between the receptor activator of NF-kappaB ligand (RANKL) and osteoprotegerin (OPG), its natural antagonist. MATERIAL/METHODS Determinations of bone marrow (BM) and serum OPG and sRANKL concentrations were performed in 133 MM patients and 42 healthy subjects by the ELISA method using Osteoprotegerin ELISA and sRANKL ELISA kits. RESULTS MM patients had elevated serum levels of OPG compared with controls (p<0.0001) and OPG levels were higher in patients with renal failure and patients with hipercalcemia (p<0.001 and p=0.04, respectively). Serum OPG levels correlated with age, serum beta 2-microglobulin, and BM OPG concentrations and did not correlate with the presence of osteolysis or with stage of disease. sRANKL serum levels in MM patients and in controls were not statistically different (p=0.42). In MM patients, serum OPG and sRANKL levels were similar at diagnosis and in the plateau phase of disease. There was a correlation between BM and serum sRANKL concentrations (p<0.001). Median values of the sRANKL/OPG ratio for BM and serum of MM patients were 0.14 and 0.11, respectively. The median value of the sRANKL/OPG ratio for the serum of controls was 0.11. CONCLUSIONS In 20% of MM patients, serum OPG levels are elevated, and this may be a compensative reaction related to increased bone destruction. There is not statistically significant relationship between sRANKL serum and BM levels and the main clinical and laboratory parameters of the disease. Determination of BM and the serum sRANKL/OPG ratio seems to have no clinical value.
Collapse
Affiliation(s)
- Maria Kraj
- Department of Hematology, Institute of Hematology and Blood Transfusion, Warsaw, Poland.
| | | | | | | | | | | |
Collapse
|
18
|
Abstract
The surface expression of CD117 antigen (c-kit) on plasma cells from 158 multiple myeloma (MM), 12 plasma cell leukemia (PCL), 7 MGUS, 7 IgM lymphoplasmacytic lymphoma patients and 10 healthy subjects has been analyzed by flow cytometry using triple staining with the monoclonal antibodies CD138, CD117 and CD38. The antigen expression intensity was calculated as relative fluorescence intensity (RFI) and for direct quantitative analysis the QuantiBRITE test (Becton Dickinson) was applied. Antibody bounding capacity (ABC) was calculated using QuantiCALC software. CD117 antigen was present in 49/158 MM, 5/12 PCL and 5/7 MGUS patients. The RFI values ranged from 0.2 to 20.2 in particular MM patients (mean: 11.0+/-5.3; median 11.5) while the number of CD117 binding sites (ABC) on MM plasma cells ranged from 637 to 6217 (mean: 3029+/-1568; median 2946) (r=0.8328). In responsive to chemotherapy c-kit positive MM patients the percentage of CD117+ plasma cells in the bone marrow decreased significantly while in c-kit negative MM patients the percentage of CD117+ cells in bone marrow did not change and remained in the normal limits. When comparing the clinical and biological disease characteristics (monoclonal protein isotype, albumin, beta2-microglobulin, lactate dehydrogenase, stage of disease, response to chemotherapy, survival time) of c-kit positive and c-kit negative cases, no significant differences were found. In CD117 positive PCL cases expression of CD117 was detected in bone marrow plasma cells as well as in peripheral blood plasma cells. Normal plasma cells and those in IgM lymphoplasmacytic lymphoma did not show reactivity for the CD117 antigen. We conclude that it may be rationale to consider usefulness of therapy with tyrosine kinase inhibitors in the management of c-kit positive plasma cell proliferations. In one third of MM and PCL patients c-kit antigen could be considered as a "tumor associated marker" and together with CD38 and CD138 it may be of value for the identification of the malignant clone in minimal residual disease as it was first suggested by Spanish authors.
Collapse
Affiliation(s)
- Maria Kraj
- Department of Hematology, Institute of Hematology and Blood Transfusion, Warsaw, Poland.
| | | | | | | | | | | |
Collapse
|
19
|
Kraj M, Pogłód R, Maj S, Pawlikowski J, Sokołowska U, Szczepanik J. Comparative evaluation of safety and efficacy of pamidronate and zoledronic acid in multiple myeloma patients (single center experience). Acta Pol Pharm 2002; 59:478-82. [PMID: 12669777] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 03/01/2023]
Abstract
Osteolytic bone destruction, caused by the aberrant production and activation of osteoclasts, results in significant morbidity for patients with multiple myeloma (MM). Pamidronate [(3-amino-1-hydroxypropylidene)-1,1-bis-phosphonate] inhibits osteoclastic activity and reduces bone resorption. A potency of zoledronic acid (2-[imidazol-1-yl]-1-hydroxyethylidene-1,1-bisphosphonic acid, a new third generation bisphosphonate, as inhibitor of resorption was 850-fold greater than pamidronate, as was shown in preclinical models of bone resorption. Randomized, double-blind study was conducted to compare the efficacy and safety of zoledronic acid and pamidronate for treating myeloma bone disease. Since March 1999 the efficacy and safety of pamidronate and zoledronic acid is evaluated in MM patients all receiving anti-myeloma chemotherapy acc. to VMCP/VBAP alternating regimen. Nine patients with stage III myeloma and osteolytic lesions (3 female, 6 male, median age 57 years, range 52-67, with monoclonal protein: IgG-7, IgA-2) were randomly assigned (1:1:1 ratio) to treatment with either 4 or 8 mg of zoledronic acid via 15-minute intravenous infusion or 90 mg of pamidronate via 2-hour intravenous infusion every 3 to 4 weeks for 12 months. All patients have received 500 mg of calcium supplements and 500 IU of vit.D, orally, once daily, for the duration of administration of study medication. In extension phase of the study (June 2000-April 2002) patients did not received bisphosphonates. In 7 patients 18 cycles of assessed treatment was administered to each of them and one patient received 16 cycles. One patient died after receiving of 12 pamidronate therapy cycles at 11 month of the trial duration (and at 49 month since MM diagnosis and anti-tumour treatment). The patient's death occurred during the progression of plasma cell proliferation due to acute left ventricle cardiac failure. During the 12-month-period of bisphosphonate treatment skeletal related events (SRE) and progression of osteolysis occurred with the same frequency in 3 treatment groups. One patient experienced spinal cord compression and received radiation to bone and 2 patients experienced vertebral fracture. Time from study entry to the first SRE was 304 days in pamidronate and 366 and 392 days in 4 and 8 mg zoledronic acid group, respectively. The skeletal morbidity rate was identical in all treatment groups. Single hypocalcemic events occurred in 2 patients, mild hypertransaminasemia was observed in 3, worsening of renal function parameters in 2 patients (transient in one of them). Muscular pain and fever up to 39 degrees C (transient and self-limiting "flu-like" symptoms) occurred in 6 patients after several or some dozens of hours from study drug administration. Adverse events were similar in nature and frequency with zoledronic acid and pamidronate and were experienced by a similar proportion of patients in each treatment group. Median time of patient's observation duration after completing of administered treatment with zoledronic acid and pamidronate amounts to 20 months. At present actual median survival time of analysed patients since MM diagnosis is 42 months, since the beginning of treatment with pamidronate and zoledronic acid--33 months, and since completing treatment--20 months and is similar in 3 treatment groups. As was shown in our single center study in MM patients the safety and efficacy of pamidronate 90 mg and zoledronic acid 4 mg and 8 mg in monthly i.v. infusion are comparable. Thus the recommended dosage of zoledronic acid is 4 mg administered as a 15 minute i.v. infusion at intervals of 3 to 4 weeks.
Collapse
Affiliation(s)
- Maria Kraj
- Institute of Haematology and Blood Transfusion, 5 Chocimska Str., 00-957 Warsaw, Poland
| | | | | | | | | | | |
Collapse
|
20
|
Kraj M, Pogłód R, Pawlikowski J, Maj S, Nasiłowska B. Effect of pamidronate on skeletal morbidity in myelomatosis. Part 1. The results of the first 12 months of pamidronate therapy. Acta Pol Pharm 2000; 57 Suppl:113-6. [PMID: 11293237] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/19/2023]
Abstract
BACKGROUND Osteolytic bone destruction caused by increase of osteolytic activity is a major manifestation of multiple myeloma (MM). Pamidronate (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate) inhibits osteoclastic activity and reduces bone resorption. METHODS Since October 1995 the efficacy of pamidronate is evaluated in MM patients all receiving anti-myeloma chemotherapy acc. to VMCP/VBAP alternating regimen. 46 patients with stage III myeloma and osteolytic lesions were randomized to receive either pamidronate (Aredia; Novartis) 60 mg i.v. in 4-hour infusion monthly (n = 23) or chemotherapy alone (control group n = 23). Estimation of performance status, quality of life, pain score, analgesic consumption, serum calcium concentration and twenty four-hours Calcium excretion, urine Calcium/creatinine ratio is done at least once a month (before pamidronate administration) while X-ray skeletal survey--before treatment and then every six months. RESULTS In the first months of treatment apparent reduction of bone pain occurred. Hypercalcaemia was revealed in 6 patients at entry into the study. In 5 of these patients pamidronate restored and maintained normocalcaemia for a median 6 months. In 3 patients an aggressive plasma cell proliferation was accompanied by reoccurrence of hypercalcaemia. At skeletal X-ray examination performed after 6 and 12 cycles of pamidronate and by comparing each of consecutive imaging with previous one the progression of osteolysis was respectively found in 67% and 39% of patients. In the control group corresponding figures were: 79% and 70%. The mean number of skeletal events (pathologic fracture, radiation to bone and spinal cord compression) per year was lower in the pamidronate group (1.82) than in control-patients (2.72), p < 0.013. The proportion of patients who developed skeletal event (excluding vertebral fractures) was lower in the pamidronate group -34% v 52%. Adverse events of pamidronate: hypocalcaemia (< 2 mmol/l) observed in 7 patients occurred in particular patients beginning from 2 to 7 days after drug administration. In 2 patients hypocalcaemia that appeared in 24 hours after drug infusion was accompanied by blood pressure decrease; in one case systolic blood pressure dropped up to 60 mmHg, in the other one--to 90 mmHg. Muscular pain and fever up to 39 degrees C (transient and self-limiting "influenza like syndrom") occurred in 5 patients, in two patients after several hours and in three other--after some dozens of hours from drug administration. In one case hypertransaminasaemia was observed. CONCLUSIONS In the first year of treatment monthly intravenous pamidronate administration as an adjunct to chemotherapy in patients with advanced multiple myeloma with osteolysis is an efficient approach in prevention and treatment of hyperacalcaemia, hypercalciuria and bone pain. It also shows some preventive effect on bone lesion occurrence.
Collapse
Affiliation(s)
- M Kraj
- Institute of Haematology and Blood Transfusion, 5 Chocimska Str., 00-957 Warsaw, Poland
| | | | | | | | | |
Collapse
|
21
|
Fabijańska-Mitek J, Zupańska B, Pogłód R, Gorajek M, Lopieńska H, Kraj M. Evaluation of the microcolumn technology for pretransfusion testing in multiple myeloma patients. Vox Sang 2000; 74:31-5. [PMID: 9481858 DOI: 10.1046/j.1423-0410.1998.7410031.x] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
OBJECTIVE Microcolumn tests are useful for serological investigations, although because of their high sensitivity, false-positive results might be expected, e.g. in hypergammaglobulinemia. The aim of this study was to evaluate these tests in multiple myeloma. METHODS Pretransfusion testing was done in 80 patients with multiple myeloma using microcolumn and traditional tube tests. RESULTS All sera were negative in microcolumn indirect antiglobulin test and enzyme test, positive in 58% of samples in the enzyme tube test. The microcolumn direct antiglobulin test was positive in about 40% of samples but never in the tube direct antiglobulin test. This was not due to the presence of autoantibodies but to nonspecific binding of immunoglobulins related to their concentration in sera. CONCLUSION Microcolumn tests appeared to be useful for pretransfusion testing in multiple myeloma in spite of positive autocontrols.
Collapse
|
22
|
MESH Headings
- Adult
- Aged
- Bone Marrow/pathology
- Female
- Follow-Up Studies
- Humans
- Incidence
- Leukemia, Myeloid/epidemiology
- Leukemia, Myeloid/mortality
- Leukemia, Myeloid/pathology
- Leukemia, Myeloid/therapy
- Leukemia, Myeloid, Acute/mortality
- Leukemia, Myeloid, Acute/pathology
- Leukemia, Myeloid, Acute/therapy
- Male
- Middle Aged
- Neoplasms, Second Primary/epidemiology
- Neoplasms, Second Primary/mortality
- Neoplasms, Second Primary/pathology
- Neoplasms, Second Primary/therapy
- Time Factors
Collapse
|
23
|
Pogłód R, Kraj M, Maj S. Effect of recombinant human granulocyte colony stimulating factor on granulocytopenia induced by cytotoxic chemotherapy in patients with multiple myeloma. Mater Med Pol 1995; 27:83-9. [PMID: 8935143] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
15 multiple myeloma patients with severe granulocytopenia after chemotherapy were treated with recombinant human granulocyte colony stimulating factor (Neupogen; Roche). Granulocyte colony stimulating factor (G-CSF) was given s.c. usually in a dose of 5 micrograms/kg for 5-14 (median:8) days. In all cases the increase in ANC was observed; one day after completing therapy the ANC ranged from 2.3 to 19.7 (mean: 10.3) x 10(9)/l. In 3 cases the ANC peak appeared during first (2-4) days of treatment, in one- on 14-th day after 10-day unsuccesful treatment. Generally, ANCs rapidly decreased after discontinuation of treatment to the values observed prior to the last chemotherapy. Both adverse events present in 9 patients and changes in monitored blood biochemistry components were moderate and reversible. In 3 cases symptoms of myeloma progression occurred. The study showed that G-CSF is an efficient and well tolerated drug, but also demonstrated its short-term action.
Collapse
Affiliation(s)
- R Pogłód
- Department of Hematology, Institute of Hematology and Blood Transfusion, Warszawa, Poland
| | | | | |
Collapse
|
24
|
Kraj M, Kopeć I, Rostkowska J, Pogłód R, Maj S. [IgM monoclonal gammopathy in plasmacytic neoplasms]. Acta Haematol Pol 1990; 21:153-65. [PMID: 2131715] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Abstract
In 331 patients with the diagnosis of multiple myeloma in 4 cases proliferation of plasma cells was associated with synthesis of a monoclonal IgM. In 3 of these cases coexistence was noted of features typical of multiple myeloma and Waldenström's macroglobulinaemia. In the clinical picture in two of these cases sings of blood hyperviscosity prevailed. These patients showed impairment of plasma clotting factors. The count of T and B cells in blood and the adherence and phagocytic activity of monocytes were not abnormal. The ultrastructural pattern of plasma cells in bone marrow was similar to that observed in classical cases of IgG or IgA multiple myeloma. In one case of lymphoplasmocytic proliferation with leucocytosis over 100 x 10(9)/l immunoelectroscopic examination of bone marrow cells demonstrated a formidable accumulation of the heavy chain of mu immunoglobulin in the cytoplasm of lymphoplasmacytes. In the serum and urine no monoclonal protein was found. In this case compression of vertebral bodies Th7 and L2 occurred.
Collapse
Affiliation(s)
- M Kraj
- Klinika Hematologiczna, Instytut Hematologii, Warszawa
| | | | | | | | | |
Collapse
|
25
|
Pogłód R. Clinical-haematological analysis of 3321 cases of proliferative diseases of the haemopoietic system treated in the Institute of Haematology in the years 1951-1980. Mater Med Pol 1990; 22:36-42. [PMID: 2079860] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Abstract
The purpose of the study was assessment of the effectiveness of treatment applied in nine proliferative diseases of the haemopoietic system (PDHS) in the years 1951-1980. The effectiveness was determined comparing the mean survival time in each of these diseases in three 10-year-time periods characterised by essential changes in their treatment. Moreover, other factors were studied which may influence the survival time in these diseases. A continuing increase in the survival time correlated with advances in therapy was observed in acute myeloid leukaemia (AML), acute lymphoblastic leukaemia (ALL), Hodgkin's disease (HD) and multiple myeloma (MM). An indicator of the advances in the treatment of acute leukaemias was also an over fourfold rise in the likelihood of achieving complete remission in the decade 1971-1980 in relation to two preceding decades. On the other hand, no improvement of the effectiveness of treatment was noted in chronic myeloid leukaemia (CML), polycythaemia vera (PV), myelofibrosis (MF) and non-Hodgkin lymphomas (NHL). The length of the survival time was influenced also considerably by patient's age (survival lower in old age), sex (better results in women) and place of residence of the patient (worse results in patients living in rural areas).
Collapse
Affiliation(s)
- R Pogłód
- Department of Haematology, Institute of Haematology, Warzawa, Poland
| |
Collapse
|
26
|
Kraj M, Maj S, Pogłód R, Rostkowska J. [Clinical usefulness of serum beta2-microglobulin determination in patients with multiple myeloma]. Acta Haematol Pol 1989; 20:140-51. [PMID: 2700533] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Abstract
Serum concentrations of beta 2-microglobulin (beta 2M) were determined in 73 patients with various forms of multiple myeloma and in various phases of the proliferative process. These determinations showed that beta 2M may be a useful indicator of changes in tumour mass and proliferation activity, and also an important prognostic factor. In patients with active proliferation the serum beta 2M concentration was significantly higher than in the group with stable proliferative process, and particularly in remission. A correlation was found between the serum concentration of monoclonal protein and beta 2M concentration. In the group with the secretory form of myeloma significant differences were showed in the length of survival which depended on beta 2M concentration in serum. The median survival of patients with beta 2M concentration in serum below 5.0 mg/l was 52 months and that in those with this concentration above 8.0 mg/l was 24 months.
Collapse
|
27
|
Kraj M, Pogłód R, Maj S. [Leukemia and other neoplasms in patients with multiple myeloma]. Nowotwory 1985; 35:64-73. [PMID: 3862075] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/07/2023]
|
28
|
Kraj M, Maj S, Pogłód R, Czajkowska E, Rostkowska J. [Neurological changes in patients with multiple myeloma]. Nowotwory 1984; 34:169-80. [PMID: 6093065] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/18/2023]
|
29
|
Kraj M, Maj S, Rostkowska J, Pogłód R, Słomkowski M. [Monochemotherapy and polychemotherapy of multiple myeloma]. Nowotwory 1984; 34:65-75. [PMID: 6377239] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/19/2023]
|